These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2757059)

  • 1. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy.
    Groop L; Schalin C; Franssila-Kallunki A; Widén E; Ekstrand A; Eriksson J
    Am J Med; 1989 Aug; 87(2):183-90. PubMed ID: 2757059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.
    Groop L; Widén E; Franssila-Kallunki A; Ekstrand A; Saloranta C; Schalin C; Eriksson J
    Diabetologia; 1989 Aug; 32(8):599-605. PubMed ID: 2506091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
    Groop LC; Bonadonna RC; DelPrato S; Ratheiser K; Zyck K; Ferrannini E; DeFronzo RA
    J Clin Invest; 1989 Jul; 84(1):205-13. PubMed ID: 2661589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonylurea treatment of insulin-independent diabetes mellitus.
    Feinglos MN; Lebovitz HE
    Metabolism; 1980 May; 29(5):488-94. PubMed ID: 6990184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus.
    Lebovitz HE
    Am J Med; 1983 Nov; 75(5B):94-9. PubMed ID: 6369972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of the second-generation sulfonylurea glipizide.
    Lebovitz HE; Feinglos MN
    Am J Med; 1983 Nov; 75(5B):46-54. PubMed ID: 6369967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with basal metabolic rate in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Franssila-Kallunki A; Groop L
    Diabetologia; 1992 Oct; 35(10):962-6. PubMed ID: 1451954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus.
    Del Prato S; Bonadonna RC; Bonora E; Gulli G; Solini A; Shank M; DeFronzo RA
    J Clin Invest; 1993 Feb; 91(2):484-94. PubMed ID: 8432857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis.
    Hardin DS; LeBlanc A; Para L; Seilheimer DK
    Diabetes; 1999 May; 48(5):1082-7. PubMed ID: 10331413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of glipizide.
    Feinglos MN; Lebovitz HE
    Am J Med; 1983 Nov; 75(5B):60-6. PubMed ID: 6369969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus.
    Bonora E; Targher G; Alberiche M; Bonadonna RC; Zenere MB; Saggiani F; Muggeo M
    J Clin Endocrinol Metab; 2001 May; 86(5):2073-9. PubMed ID: 11344209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus.
    Borissova AM; Koev DG; Minev MG; Martinova FG; Gencova PI; Kirilov GG; Arnaudov J
    Acta Diabetol Lat; 1991; 28(1):91-8. PubMed ID: 1862695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects.
    Keller U; Müller R; Berger W
    Horm Metab Res; 1986 Sep; 18(9):599-603. PubMed ID: 2946637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.
    Lebovitz HE
    Pharmacotherapy; 1985; 5(2):63-77. PubMed ID: 3923454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.